LIP
RLMD icon

Lighthouse Investment Partners’s Relmada Therapeutics RLMD Stock Holding History

Lighthouse Investment Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,960
Closed -$77.1K – 1009
2025
Q4 		$77.1K Buy
+15,960
New +$53.5K ﹤0.01% 824

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Lighthouse Investment Partners's RLMD Position: Q1 2026 in Review

Lighthouse Investment Partners sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 15,960 shares — an estimated $77.1K sold.

Lighthouse Investment Partners first reported a position in RLMD in Q4 2025 and held it in 1 quarter. The position peaked at $77.1K in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Lighthouse Investment Partners reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lighthouse Investment Partners sold 15,960 Relmada Therapeutics shares in Q1 2026, an estimated $77.1K.
  • Lighthouse Investment Partners first reported a position in Relmada Therapeutics in Q4 2025 and held it in 1 quarter.
  • Lighthouse Investment Partners's Relmada Therapeutics position peaked at $77.1K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Lighthouse Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.